HC Wainwright Comments on Kura Oncology Q1 Earnings

Kura Oncology, Inc. (NASDAQ:KURA) – Equities research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Kura Oncology in a research report issued to clients and investors on Thursday, February 27th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.80) for the quarter. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Kura Oncology’s current full-year earnings is ($2.44) per share. HC Wainwright also issued estimates for Kura Oncology’s Q3 2025 earnings at ($0.76) EPS and Q4 2025 earnings at ($0.78) EPS.

KURA has been the subject of a number of other reports. BTIG Research downgraded Kura Oncology from a “buy” rating to a “neutral” rating in a report on Thursday, February 6th. JMP Securities reiterated a “market outperform” rating and issued a $28.00 target price on shares of Kura Oncology in a research note on Thursday, February 6th. Bank of America lowered their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a report on Friday, November 22nd. Scotiabank cut their price objective on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a report on Wednesday, January 8th. Finally, Jefferies Financial Group lowered their target price on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research note on Thursday, November 21st. Four analysts have rated the stock with a hold rating, eight have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $27.13.

Kura Oncology Stock Performance

NASDAQ KURA opened at $7.65 on Friday. Kura Oncology has a fifty-two week low of $6.98 and a fifty-two week high of $24.17. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. The firm has a market capitalization of $594.89 million, a P/E ratio of -3.24 and a beta of 0.78. The stock has a 50-day simple moving average of $8.19 and a two-hundred day simple moving average of $13.92.

Kura Oncology (NASDAQ:KURA) last posted its earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.43. The business had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million.

Insider Buying and Selling

In other news, insider Mollie Leoni sold 4,963 shares of the firm’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $38,948.63. Following the sale, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. The trade was a 5.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 11,729 shares of company stock worth $92,307. Insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Kura Oncology

A number of hedge funds have recently modified their holdings of KURA. Barclays PLC grew its stake in Kura Oncology by 104.5% during the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after acquiring an additional 84,563 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Kura Oncology in the fourth quarter valued at approximately $436,000. Moody Aldrich Partners LLC grew its position in shares of Kura Oncology by 42.3% in the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock valued at $1,251,000 after purchasing an additional 42,712 shares in the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of Kura Oncology by 4.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock valued at $430,000 after purchasing an additional 2,076 shares during the last quarter. Finally, Jennison Associates LLC acquired a new position in Kura Oncology during the fourth quarter worth $623,000.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.